Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Plus Therapeutics ( (PSTV) ) just unveiled an update.
On April 20, 2026, Plus Therapeutics received notice from Nasdaq that it had regained compliance with the exchange’s minimum bid price requirement for continued listing on the Nasdaq Capital Market. The compliance followed a one-for-twenty-five reverse stock split of the company’s common shares that became effective on April 2, 2026, and Nasdaq confirmed that the stock closed at or above $1.00 for ten consecutive trading days from April 6 to April 17, 2026, effectively closing the listing deficiency matter and stabilizing the firm’s market status.
The company disclosed the notification in an April 21, 2026 press release, signaling a resolution to prior listing concerns that had posed a risk to its Nasdaq status. Restored compliance helps preserve Plus Therapeutics’ access to public capital markets and visibility among institutional investors at a time when it is advancing clinical-stage radiotherapeutic programs for central nervous system cancers.
The most recent analyst rating on (PSTV) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
Spark’s Take on PSTV Stock
According to Spark, TipRanks’ AI Analyst, PSTV is a Neutral.
The score is primarily held down by very weak financial performance (zero revenue in 2025, widening losses, and accelerating cash burn). Technicals are mixed with only short-term strength against a longer-term downtrend. Valuation is also constrained by a negative P/E and no dividend data.
To see Spark’s full report on PSTV stock, click here.
More about Plus Therapeutics
Plus Therapeutics, Inc., based in Houston, Texas, is a clinical-stage pharmaceutical company focused on developing and commercializing targeted radiotherapeutics and precision diagnostics for difficult-to-treat central nervous system cancers. Leveraging image-guided local beta radiation and targeted drug delivery, the company is advancing product candidates led by programs in leptomeningeal metastases and recurrent glioblastoma, supported by a supply-chain built through strategic partnerships.
Average Trading Volume: 437,265
Technical Sentiment Signal: Sell
Current Market Cap: $38.77M
See more data about PSTV stock on TipRanks’ Stock Analysis page.